
USD
$0.00
(0.00%
)At Close (As of Dec 15, 2025)
$9.69B
Market Cap
-
P/E Ratio
-0.01
EPS
$72.36
52 Week High
$9.57
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $829M |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | $98M |
| Selling General And Administrative | $124M |
| Research And Development | $607M |
| Operating Expenses | $731M |
| Investment Income Net | - |
| Net Interest Income | -$52M |
| Interest Income | $37M |
| Interest Expense | $89M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | $20M |
| Income Tax Expense | $21M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $30M |
| Comprehensive Income Net Of Tax | - |
| Ebit | - |
| Ebitda | $98M |
| Net Income | -$1.6M |
| Field | Value (USD) |
|---|---|
| Total Assets | $1.5B |
| Total Current Assets | $951M |
| Cash And Cash Equivalents At Carrying Value | $227M |
| Cash And Short Term Investments | $227M |
| Inventory | - |
| Current Net Receivables | $6.8M |
| Total Non Current Assets | $500M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $6.9M |
| Intangible Assets Excluding Goodwill | $6.9M |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $693M |
| Other Current Assets | $24M |
| Other Non Current Assets | - |
| Total Liabilities | $947M |
| Total Current Liabilities | $195M |
| Current Accounts Payable | $18M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $47M |
| Total Non Current Liabilities | $752M |
| Capital Lease Obligations | $111M |
| Long Term Debt | $215M |
| Current Long Term Debt | $40M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $734M |
| Other Current Liabilities | $128M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $466M |
| Treasury Stock | - |
| Retained Earnings | -$1.6B |
| Common Stock | $231K |
| Common Stock Shares Outstanding | $134M |
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $829M |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | $98M |
| Selling General And Administrative | $124M |
| Research And Development | $607M |
| Operating Expenses | $731M |
| Investment Income Net | - |
| Net Interest Income | -$52M |
| Interest Income | $37M |
| Interest Expense | $89M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | $20M |
| Income Tax Expense | $21M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $30M |
| Comprehensive Income Net Of Tax | - |
| Ebit | - |
| Ebitda | $98M |
| Net Income | -$1.6M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Arrowhead Pharmaceuticals Inc. is a leading clinical-stage biopharmaceutical company based in Pasadena, California, specializing in pioneering RNA interference (RNAi) technology to develop innovative therapies for liver disorders and genetic diseases. With an extensive pipeline of drug candidates, Arrowhead is committed to advancing the frontiers of gene silencing and targeted therapeutics, addressing pivotal unmet medical needs. The company’s strategic partnerships bolster its research capabilities and clinical development efforts, positioning Arrowhead to potentially redefine treatment approaches within the biopharmaceutical industry and deliver significant value to patients and investors alike.